Press release
Investigation announced for Investors in NASDAQ: CORT shares concerning possible Securities Laws Violations by Corcept Therapeutics Incorporated
An investigation for investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) shares over potential securities laws violation
Investors who purchased shares of Corcept Therapeutics Incorporated (NASDAQ: CORT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Corcept Therapeutics Incorporated (NASDAQ: CORT) concerning whether a series of statements by Corcept Therapeutics Incorporated regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Menlo Park, CA based Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. Corcept Therapeutics Incorporated reported that its annual Total Revenue rose from $306.48 million in 2019 to $353.87 million in 2020, and that its Net Income increased from $94.18 million in 2019 to $106.01 million in 2020.
On December 8, 2021, Corcept Therapeutics Incorporated disclosed in a filing with the U.S. Securities and Exchange Commission that "[o]n November 15, 2021, the Company received a records subpoena from the U.S. Attorney's Office for the District of New Jersey (the 'NJ USAO') pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) seeking information relating to the sale and promotion of Korlym, Corcept's relationships with and payments to health care professionals who can prescribe or recommend Korlym and prior authorizations and reimbursement for Korlym." Corcept further disclosed that "[t]he NJ USAO has informed Corcept that it is investigating whether any criminal or civil violations by Corcept occurred in connection with the matters referenced in the subpoena."
Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) declined from $23.94 per share on November 17, 2021, to as low as $15.83 per share on December 8, 2021.
Those who purchased shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in NASDAQ: CORT shares concerning possible Securities Laws Violations by Corcept Therapeutics Incorporated here
News-ID: 2543705 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Corcept
Cushings Syndrome Market to Witness Groundbreaking Innovations by 2025 - 2032 | …
The Cushing's disease treatment market was valued at USD 14.95 billion in 2025 and is anticipated to grow to USD 37.41 billion by 2032, registering a CAGR of 14% during the forecast period
The Cushings Syndrome Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers. It encompasses a wide range of critical factors influencing the Cushings Syndrome Market, including competitive landscape, consumer…
Abortion Drugs Market Overall Study Report 2024-2031 | Corcept Therapeutics Inc. …
Abortion Drugs Market Trends Overview 2024-2031:
A new Report by Coherent Market Insights, titled "Abortion Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the Abortion Drugs market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
This report has a complete table of contents, figures, tables, and charts, as well as insightful…
Cushing's Disease Treatment Market May See a Big Move | Major Giants CORCEPT THE …
The new report by Stratagem Market Insights titled, "Global Cushing's Disease Treatment Market Outlook Report 2022-2030", gives an in-depth analysis of the global Cushing's Disease Treatment market, assessing the market based on its segments like Type, Application, and Major Regions. A detailed study accumulated to offer the latest insights about acute features of the Cushing's Disease Treatment market. The report contains different market predictions related to Revenue Size, Production, CAGR,…
Investigation announced for Long-Term Investors in shares of Corcept Therapeutic …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Corcept Therapeutics Incorporated.
Investors who purchased shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) and currently hold any of those NASDAQ: CORT shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Corcept Therapeutics Incorporated directors breached their fiduciary duties and caused…
Corcept Therapeutics Incorporated (NASDAQ: CORT) Investor Notice: Update on Laws …
The Shareholders Foundation announced an update in the lawsuit that is pending for certain investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) shares.
Investors who purchased shares of Corcept Therapeutics Incorporated (NASDAQ: CORT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
On March 14, 2019, a lawsuit was filed against Corcept Therapeutics Incorporated over alleged securities laws violations. The plaintiff alleged that the defendants…
Glucocorticoid Receptor (GR) Antagonist Market 2020 Clinical Area Segmentation â …
Glucocorticoid Receptor (GR) Antagonist -Pipeline Insight, 2020
The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Glucocorticoid Receptor (GR) Antagonist Market on the basis of stating current situation of the industry in 2020.
This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of…
